An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2015
At a glance
- Drugs FP 1039 (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Five Prime Therapeutics
- 09 Mar 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 31 Oct 2011 Additional locations identified as reported by ClinicalTrials.gov.
- 18 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.